Acquisition by Leah Neufeld of 60500 shares of Immuneering Corp at 6.09 subject to Rule 16b-3

IMRX Stock  USD 2.06  0.07  3.29%   
Slightly above 54% of Immuneering Corp's investor base is interested to short. The analysis of the overall investor sentiment regarding Immuneering Corp suggests that many traders are impartial. Immuneering Corp's investing sentiment can be driven by a variety of factors including economic data, Immuneering Corp's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Immuneering Corp Officer Chief People Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 60500 stock option at 6.09 of Immuneering Corp by Leah Neufeld on 31st of October 2024. This event was filed by Immuneering Corp with SEC on 2024-02-08. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Immuneering Corp's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Immuneering Corp's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Immuneering Corp Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Immuneering Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Immuneering Corp Fundamental Analysis

We analyze Immuneering Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immuneering Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immuneering Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Immuneering Corp is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Immuneering Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immuneering Corp stock to make a market-neutral strategy. Peer analysis of Immuneering Corp could also be used in its relative valuation, which is a method of valuing Immuneering Corp by comparing valuation metrics with similar companies.

Peers

Immuneering Corp Related Equities

KRONKronos Bio   10.34   
0%
100.0%
LRMRLarimar Therapeutics   7.44   
0%
71.0%
GOSSGossamer Bio   6.06   
0%
58.0%
GLUEMonte Rosa   5.93   
0%
57.0%
ELVNEnliven Therapeutics   4.35   
0%
42.0%
CMPXCompass Therapeutics   3.31   
0%
32.0%
NVCTNuvectis Pharma   2.52   
0%
24.0%
CGEMCullinan Oncology   2.51   
0%
24.0%
CNTACentessa Pharmaceuticals   1.73   
0%
16.0%
IVAInventiva   1.52   
0%
14.0%
PMVPPmv Pharmaceuticals   0.63   
0%
6.0%
NAMSNewAmsterdam Pharma   0.19   
1.0%
0%
IKNAIkena Oncology   1.17   
11.0%
0%
CELCCelcuity LLC   1.53   
14.0%
0%
REPLReplimune   2.29   
22.0%
0%
LYRALyra Therapeutics   5.00   
48.0%
0%

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.